Qiagen (QGEN) reported $2.1B in revenue for fiscal 2025, +5.7% year on year. That ranks #1313 by revenue among 2853 SEC filers and #119 in Healthcare. Net income was $425M, a net margin of 20.3%. Revenue has grown 5.1% a year on average since 2016 ($1.3B then). The fiscal 2025 balance sheet shows $6.3B in total assets, $839M in cash and $1.7B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $2.1B | +5.7% | FY20252025-12-31 |
| Gross profitGrossProfit | $1.3B | +34.3% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $466M | +376.8% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $425M | +408.3% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $654M | −2.9% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $201M | +20.3% | FY20252025-12-31 |
| Total assetsAssets | $6.3B | +10.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $3.8B | +5.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $839M | +26.4% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $1.7B | +97.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 24 of 161 companies compared | 20.3% | |
| Operating marginRank 29 of 160 companies compared | 22.3% | |
| R&D as share of revenueRank 48 of 102 companies compared | 9.0% | |
| Cash as share of revenueRank 16 of 160 companies compared | 40.1% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Qiagen N.V.
- Ticker
- QGEN
- Exchange
- NYSE
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0001015820
Filings
- 20-FMar 20, 2026Open filing →
- 20-FMar 31, 2025Open filing →
- 20-FMar 11, 2024Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Sarepta TherapeuticsSRPT | $2.2B | −$713M |
| Concentra Group Holdings ParentCON | $2.2B | $166M |
| Privia HealthPRVA | $2.1B | $22.9M |
| QiagenQGEN | $2.1B | $425M |
| RadnetRDNT | $2.0B | −$18.7M |
| TeleflexTFX | $2.0B | −$906M |
| National VisionEYE | $2.0B | $29.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Qiagen — Key figures |url=https://companiesranked.com/en/company/qiagen |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Qiagen — Key figures. CompaniesRanked. https://companiesranked.com/en/company/qiagenBibTeX
@misc{companiesranked-en-company-qiagen-2026,
author = {{CompaniesRanked}},
title = {{Qiagen — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/qiagen}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001015820-26-000018 · March 20, 2026
{{cite web |title=Qiagen — Key figures — 20-F (0001015820-26-000018) |url=https://www.sec.gov/Archives/edgar/data/1015820/000101582026000018/qgen-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-20}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.